Evidence for separation of HCV subtype 1a into two distinct clades

Journal of Viral Hepatitis

Volumn 18, Issue 9, 2011, Pages 608-618

  Pickett, B E ^a   Striker, R ^b,c   Lefkowitz, E J ^a  

^a University of Alabama at Birmingham   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

bioinformatics; drug resistance; hepatitis C virus; phylogeny; selection pressure

Indexed keywords

AMINO ACID; POLYPROTEIN; PROTEINASE INHIBITOR; RNA POLYMERASE;

ARTICLE; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 1A; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; VIRUS ISOLATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; BASE SEQUENCE; CODON; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; MUTATION; PHYLOGENY; PROTEASE INHIBITORS; SELECTION, GENETIC; SEQUENCE ALIGNMENT; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 79960937707     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01342.x     Document Type: Article

References (55)

1. Alter MJ,. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13 (17): 2436-2441. (Pubitemid 46929498)
2. Lemon SM, Walker C, Alter MJ, Yi M,. Hepatitis C Virus. Philadelphia, PA: Lippincott Williams & Wilkins, 2007.
3. Walewski JL, Keller TR, Stump DD, Branch AD,. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA, 2001; 7 (5): 710-721. (Pubitemid 32405868)
4. Vassilaki N, Mavromara P,. Two alternative translation mechanisms are responsible for the expression of the HCV ARFP/F/core+1 coding open reading frame. J Biol Chem 2003; 278 (42): 40503-40513. (Pubitemid 37280860)
5. Dhar D, Mapa K, Pudi R, Srinivasan P, Bodhinathan K, Das S,. Human ribosomal protein L18a interacts with hepatitis C virus internal ribosome entry site. Arch Virol 2006; 151 (3): 509-524.
6. Ali N, Pruijn GJ, Kenan DJ, Keene JD, Siddiqui A,. Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. J Biol Chem 2000; 275 (36): 27531-27540.
7. Simmonds P,. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004; 85 (Pt 11): 3173-3188. (Pubitemid 39445434)
8. Kurosaki M, Enomoto N, Marumo F, Sato C,. Evolution and selection of hepatitis C virus variants in patients with chronic hepatitis C. Virology 1994; 205 (1): 161-169. (Pubitemid 24360602)
9. Zeuzem S,. Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy. Forum (Genova) 2000; 10 (1): 32-42. (Pubitemid 30160684)
10. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74 (Pt 11): 2391-2399. (Pubitemid 23332300)
11. Bukh J, Miller RH, Purcell RH,. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15 (1): 41-63.
12. Donlin MJ, Cannon NA, Yao E, et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007; 81 (15): 8211-8224. (Pubitemid 47101507)
13. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347 (13): 975-982.
14. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130 (4): 1086-1097.
15. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131 (2): 470-477. (Pubitemid 44142464)
16. Cannon NA, Donlin MJ, Fan X, Aurora R, Tavis JE,. Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy. PLoS ONE 2008; 3 (5): e2123.
17. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (Baltimore, MD) 2007; 46 (3): 631-639. (Pubitemid 47436107)
18. Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Viral Hepat 2008; 15 (3): 188-199. (Pubitemid 351146581)
19. Greene JM, Collins F, Lefkowitz EJ, et al. National institute of allergy and infectious diseases bioinformatics resource centers: new assets for pathogen informatics. Infect Immun 2007; 75 (7): 3212-3219. (Pubitemid 47040922)
20. Edgar RC,. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 2004; 32 (5): 1792-1797. (Pubitemid 38832724)
21. Thompson JD, Higgins DG, Gibson TJ,. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22 (22): 4673-4680. (Pubitemid 24354800)
22. Tamura K, Dudley J, Nei M, Kumar S,. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24 (8): 1596-1599. (Pubitemid 47236692)
23. Korber B,. HIV signature and sequence variation analysis. In:, Rodrigo AG, Learn GH, eds. Computational Analysis of HIV Molecular Sequences. Dordrecht, Netherlands: Kluwer Academic Publishers, 2000: 55-72.
24. Auguste AJ, Pybus OG, Carrington CV,. Evolution and dispersal of St Louis encephalitis virus in the Americas. Infect Genet Evol 2009; 9 (4): 709-715.
25. Bragstad K, Nielsen LP, Fomsgaard A,. The evolution of human influenza A viruses from 1999 to 2006: a complete genome study. Virol J 2008; 5: 40.
26. Curry S, Qiu P, Tong X,. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay. J Virol Methods 2008; 153 (2): 156-162.
27. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology (Baltimore, MD) 2008; 48 (6): 1769-1778.
28. Nei M, Gojobori T,. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol Biol Evol 1986; 3 (5): 418-426. (Pubitemid 16010523)
29. Lee MA, Keane OM, Glass BC, et al. Establishment of a pipeline to analyse non-synonymous SNPs in Bos taurus. BMC Genomics 2006; 7: 298.
30. Crick FH,. Codon-anticodon pairing: the wobble hypothesis. J Mol Biol 1966; 19 (2): 548-555.
31. Yang Z,. Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol Biol Evol 1998; 15 (5): 568-573. (Pubitemid 28194621)
32. Ganeshan S, Dickover RE, Korber BT, Bryson YJ, Wolinsky SM,. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease. J Virol 1997; 71 (1): 663-677. (Pubitemid 26412340)
33. Unemo M, Olcen P, Albert J, Fredlund H,. Comparison of serologic and genetic porB-based typing of Neisseria gonorrhoeae: consequences for future characterization. J Clin Microbiol 2003; 41 (9): 4141-4147. (Pubitemid 37099677)
34. Mindell DP,. Positive selection and rates of evolution in immunodeficiency viruses from humans and chimpanzees. Proc Natl Acad Sci USA 1996; 93 (8): 3284-3288. (Pubitemid 26125610)
35. von Hahn T, Yoon JC, Alter H, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132 (2): 667-678. (Pubitemid 46274668)
36. Kuntzen T, Timm J, Berical A, et al. Viral sequence evolution in acute hepatitis C virus infection. J Virol 2007; 81 (21): 11658-11668. (Pubitemid 47623798)
37. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC,. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology (Baltimore, MD) 1998; 27 (1): 223-227. (Pubitemid 28041558)
38. Li H, McMahon BJ, McArdle S, et al. Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology 2008; 375 (2): 580-591.
39. Sheridan I, Pybus OG, Holmes EC, Klenerman P,. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 2004; 78 (7): 3447-3454. (Pubitemid 38568286)
40. Shimizu YK, Igarashi H, Kiyohara T, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996; 223 (2): 409-412. (Pubitemid 26319606)
41. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93 (26): 15394-15399. (Pubitemid 27009611)
42. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (New York, NY) 2000; 288 (5464): 339-344. (Pubitemid 30226196)
43. Mink MA, Benichou S, Madaule P, Tiollais P, Prince AM, Inchauspe G,. Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library. Virology 1994; 200 (1): 246-255. (Pubitemid 24170474)
44. Zibert A, Kraas W, Ross RS, et al. Immunodominant B-cell domains of hepatitis C virus envelope proteins E1 and E2 identified during early and late time points of infection. J Hepatol 1999; 30 (2): 177-184. (Pubitemid 29071177)
45. Ching WM, Wychowski C, Beach MJ, et al. Interaction of immune sera with synthetic peptides corresponding to the structural protein region of hepatitis C virus. Proc Natl Acad Sci USA 1992; 89 (8): 3190-3194.
46. Schulze zur Wiesch J, Lauer GM, Day CL, et al. Broad repertoire of the CD4 + Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005; 175 (6): 3603-3613. (Pubitemid 41292019)
47. Xu Z, Choi J, Yen TS, et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J 2001; 20 (14): 3840-3848. (Pubitemid 32691795)
48. Reed KE, Rice CM,. Identification of the major phosphorylation site of the hepatitis C virus H strain NS5A protein as serine 2321. J Biol Chem 1999; 274 (39): 28011-28018.
49. Robida JM, Nelson HB, Liu Z, Tang H,. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol 2007; 81 (11): 5829-5840. (Pubitemid 46847020)
50. Zhou Y, Muh U, Hanzelka BL, et al. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. J Biol Chem 2007; 282 (31): 22619-22628. (Pubitemid 47267330)
51. Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA,. Hepatitis C virus NS3/4A protease. Antiviral Res 1999; 41 (1): 67-84.
52. Fernandes F, Poole DS, Hoover S, et al. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology (Baltimore, MD) 2007; 46 (4): 1026-1033. (Pubitemid 350144767)
53. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Eng J Med 1996; 334 (2): 77-81. (Pubitemid 26017933)
54. Torres-Puente M, Cuevas JM, Jimenez-Hernandez N, et al. Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment. J Med Virol 2008; 80 (2): 247-253.
55. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993; 74 (Pt 11): 2385-2390. (Pubitemid 23332299)